View Older Stories View More Recent Stories

Oct 3, 2022 01:01PM Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Sep 26, 2022 06:45AM BioNTech SE (BNTX) and Pfizer (PFE) Submit FDA Application for EMA of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children Aged 5-11
Sep 26, 2022 06:45AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
Sep 26, 2022 06:45AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
Sep 22, 2022 08:00AM Pfizer Declares Fourth-Quarter 2022 Dividend
Sep 22, 2022 06:45AM Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries
Sep 20, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts
Sep 19, 2022 06:45AM Pfizer (PFE) Reports Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in EU
Sep 19, 2022 06:45AM Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union
Sep 16, 2022 08:00AM Pfizer (PFE), BioNTech (BNTX) Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Sep 16, 2022 08:00AM Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Sep 15, 2022 06:45AM Pfizer (PFE) Reports Positive Top-Line Results from Phase 3 Trial of MenABCWY
Sep 15, 2022 06:45AM Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
Sep 14, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022
Sep 14, 2022 06:45AM Pfizer (PFE) Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
Sep 14, 2022 06:45AM Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
Sep 12, 2022 11:20AM Pfizer (PFE), BioNTech (BNTX) Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 12, 2022 11:20AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 12, 2022 11:20AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 9, 2022 06:47AM Pfizer (PFE) Announces FDA and EMA Acceptance of Ritlecitinib for Alopecia Areata
Sep 9, 2022 06:45AM FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata
Sep 7, 2022 06:51AM Pfizer (PFE) Group B Streptococcus Vaccine Candidate Granted FDA Breakthrough Therapy Designation
Sep 7, 2022 06:45AM FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
Sep 6, 2022 11:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Sep 6, 2022 10:00AM Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action
Sep 1, 2022 10:00AM Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
Sep 1, 2022 09:46AM BioNTech SE (BNTX) and Pfizer (PFE) Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in EU
Sep 1, 2022 09:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 1, 2022 09:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Aug 31, 2022 10:18AM Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Aug 31, 2022 10:15AM Pfizer (PFE), BioNTech SE (BNTX) Confirm FDA EUA for Omicron Booster
Aug 31, 2022 10:12AM Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Aug 26, 2022 09:52AM  Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Aug 26, 2022 09:45AM Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Aug 25, 2022 06:45AM Pfizer (PFE) Reports Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Aug 25, 2022 06:45AM Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Aug 23, 2022 06:45AM Pfizer (PFE) and BioNTech (BNTX) Report Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years Old
Aug 23, 2022 06:45AM Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Aug 23, 2022 06:45AM Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Aug 22, 2022 10:31AM BioNTech SE (BNTX) and Pfizer (PFE) Submit FDA Application for EMA of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Aug 22, 2022 10:30AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Aug 22, 2022 10:30AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Aug 19, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Aug 15, 2022 05:00PM ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results
Aug 12, 2022 06:46AM Pfizer (PFE) Reports Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
Aug 12, 2022 06:45AM Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
Aug 8, 2022 04:47PM Pfizer (PFE) and Valneva (VALN) Initiate Phase 3 Study of VLA15
Aug 8, 2022 04:45PM Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Aug 8, 2022 04:45PM Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Aug 8, 2022 06:46AM Pfizer (PFE) to Acquire Global Blood Therapeutics (GBT) for $5.4 Billion, $68.50 Per Share
View More Recent Stories View Older Stories